Digital Therapeutics Users to Exceed 40 Million in the US by 2026

The number of people using digital therapeutics in the US will grow by 510% over the next four years; from 7 million in 2022 to over 40 million by 2026, according to Juniper Research. This spectacular growth will be driven by the increasing prevalence of diabetes in the US, allied with recent initiatives to expand digital therapeutics coverage and cost reimbursement, such as the newly introduced Access to Prescription Digital Therapeutics Act.

The research predicts the leading digital therapeutics vendors will pivot from condition-specific therapeutics towards therapeutics that target multiple conditions; enabling patients and clinicians to target chronic conditions and associated comorbidities within a single solution, as opposed to several non-interoperable therapeutics by competing vendors. The report warned that few digital therapeutics solutions are interoperable with larger healthcare systems; reducing their effectiveness and ability to drive improvements in patient healthcare outcomes. It warned that vendors must prioritize interoperability, with larger healthcare industry standards such as Fast Healthcare Interoperability Resources.

The research reviewed the top 15 digital therapeutics vendors in the market and evaluated key factors that led to their respective success. Juniper Research ranked Omada Health as leading this market, based on its expansive portfolio of clinically-validated digital therapeutics, including a revolutionary physician-guided care program targeting diabetes and hypertension. It suggests competitors emulate its strategy of innovating digital therapeutics that target multiple conditions and comorbidities, as opposed to single condition-targeting therapeutics, as these solutions are more likely to gain traction among stakeholders such as payers, healthcare institutions, and employers.